In this issue of the HCV Advocate’s Mid-Month edition we present the following:
In this month’s Mid-Month Edition of the HCV newsletter we have some exciting articles to share with you:
– read about the news from the Food and Drug Administration (FDA) about sofosbuvir plus velpatasvir and the cure rates for genotypes 1 through 6. There is more news from the FDA about Viekira Pak without ribavirin to treat genotype 1b, and Merck’s pending FDA approval. Lastly, there is some good news about easing of some insurance restrictions.
—this month’s edition has a study about the possible link between hepatitis C and inclusion body myositis, improvements in liver functioning after a cure in people with advanced liver disease, tests to gauge surviving the liver transplant waiting list, and finally a possible link between Parkinson’s disease and hepatitis C.
—Hepatitis C: A Waiting Exercise
– most exercise is good for you—this article is more about exercising the mind, body, spirit, and patience while waiting for treatment.
There is information about our updated Herbal Glossary, Events Page, our blog and a request for your input on our support group database.
Alan and the staff of the HCV Advocate